{"id":696205,"date":"2024-04-24T09:18:01","date_gmt":"2024-04-24T09:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=696205"},"modified":"2024-04-24T09:18:01","modified_gmt":"2024-04-24T09:18:01","slug":"leptomeningeal-metastases-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-plus-therapeutics-ymabs-therapeutics-angiochem-unicancer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/leptomeningeal-metastases-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-plus-therapeutics-ymabs-therapeutics-angiochem-unicancer_696205.html","title":{"rendered":"Leptomeningeal Metastases Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Plus Therapeutics, Y-mAbs Therapeutics, Angiochem, UNICANCER"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1713787867.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Leptomeningeal Metastases Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Plus Therapeutics, Y-mAbs Therapeutics, Angiochem, UNICANCER\" src=\"https:\/\/www.abnewswire.com\/uploads\/1713787867.jpeg\" alt=\"Leptomeningeal Metastases Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Plus Therapeutics, Y-mAbs Therapeutics, Angiochem, UNICANCER\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Leptomeningeal Metastases Market  size was valued at USD 1,275.4 Million in the year 2021 and the report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\">The Leptomeningeal Metastases market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Leptomeningeal Metastases pipeline products will significantly revolutionize the Leptomeningeal Metastases market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Leptomeningeal Metastases market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/leptomeningeal-metastases-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Leptomeningeal Metastases Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Leptomeningeal Metastases Market Report: &nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Leptomeningeal Metastases market size was valued at <strong>USD 1,275.4 Million in the year 2021<\/strong> and is anticipated to grow with a significant CAGR during the study period (2019-2032)&nbsp;<\/li>\n<li>The United States accounted for the highest market size among the 7MM countries accounting for <strong>USD 708.9 Million<\/strong> in the year 2021&nbsp;<\/li>\n<li>According to DelveInsight&#8217;s projections, in 2023, the total diagnosed cases of Leptomeningeal Metastases were approximately <strong>300,000 cases<\/strong> in the 7MM. These numbers are anticipated to increase throughout the study period from 2020 to 2034.<\/li>\n<li>According to DelveInsight&#8217;s projections, in 2023, there were approximately 60,000 diagnosed cases of Leptomeningeal Metastases in Japan. These figures are anticipated to increase during the study period from 2020 to 2034.<\/li>\n<li>In 2023, around 240,000 cases of Leptomeningeal Metastases were treated in the 7MM.<\/li>\n<li><strong>Key Leptomeningeal Metastases Companies:<\/strong> Plus Therapeutics, Y-mAbs Therapeutics, Angiochem, UNICANCER, TYK Medicines, Inc, MedSIR, and others<\/li>\n<li><strong>Key Leptomeningeal Metastases Therapies:<\/strong> Rhenium-186 NanoLiposome (186RNL), Omburtamab, Paclitaxel trevatide (ANG1005), Tucatinib Oral Tablet, TY-9591 Tablets, Patritumab deruxtecan, and others<\/li>\n<li>Leptomeningeal metastasis is considered the third most common metastatic complication involving the central nervous system (CNS)&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Leptomeningeal Metastases Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Leptomeningeal metastases (LM), also known as leptomeningeal carcinomatosis or leptomeningeal disease, are a rare but serious complication of cancer where cancer cells spread to the thin layers of tissue that cover the brain and spinal cord, known as the leptomeninges. These layers include the arachnoid and pia mater, and together they form the leptomeninges.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Get a Free sample for the Leptomeningeal Metastases Market Report:&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/leptomeningeal-metastases-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/leptomeningeal-metastases-market<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Leptomeningeal Metastases Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Leptomeningeal Metastases Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Leptomeningeal Metastases market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Leptomeningeal Metastases<\/li>\n<li>Prevalent Cases of Leptomeningeal Metastases by severity<\/li>\n<li>Gender-specific Prevalence of Leptomeningeal Metastases<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Leptomeningeal Metastases&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Leptomeningeal Metastases epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/leptomeningeal-metastases-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Leptomeningeal Metastases Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Leptomeningeal Metastases Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Rhenium-186 NanoLiposome (186RNL):<\/strong> Plus Therapeutics<\/li>\n<li><strong>Omburtamab:<\/strong> Y-mAbs Therapeutics<\/li>\n<li><strong>Paclitaxel trevatide (ANG1005):<\/strong> Angiochem<\/li>\n<li><strong>Tucatinib Oral Tablet:<\/strong> UNICANCER<\/li>\n<li><strong>TY-9591 Tablets:<\/strong> TYK Medicines, Inc<\/li>\n<li><strong>Patritumab deruxtecan:<\/strong> MedSIR<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Leptomeningeal Metastases treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/leptomeningeal-metastases-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Leptomeningeal Metastases Medications<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Leptomeningeal Metastases Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Researchers are working on newer, more accurate diagnostic tests looking for DNA signatures, which can be used to diagnose patients more accurately<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Leptomeningeal Metastases Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Currently, there is no approved treatment for the disease; as a result, it is an opportune time for the companies to investigate unmet requirements and develop therapeutic choices that will benefit the patient population and leverage this orphan indication.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Leptomeningeal Metastases Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Leptomeningeal Metastases Companies:<\/strong> Plus Therapeutics, Y-mAbs Therapeutics, Angiochem, UNICANCER, TYK Medicines, Inc, MedSIR, and others<\/li>\n<li><strong>Key Leptomeningeal Metastases Therapies:<\/strong> 1Rhenium-186 NanoLiposome (186RNL), Omburtamab, Paclitaxel trevatide (ANG1005), Tucatinib Oral Tablet, TY-9591 Tablets, Patritumab deruxtecan, and others<\/li>\n<li><strong>Leptomeningeal Metastases Therapeutic Assessment:<\/strong> Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies<\/li>\n<li><strong>Leptomeningeal Metastases Market Dynamics:&nbsp;<\/strong>Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Leptomeningeal Metastases Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Leptomeningeal Metastases Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Leptomeningeal Metastases market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/leptomeningeal-metastases-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Leptomeningeal Metastases market forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Leptomeningeal Metastases Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Leptomeningeal Metastases<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Leptomeningeal Metastases<\/p>\n<p style=\"text-align: justify;\">4. Leptomeningeal Metastases Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Leptomeningeal Metastases Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Leptomeningeal Metastases Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Leptomeningeal Metastases Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Leptomeningeal Metastases&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Leptomeningeal Metastases Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Leptomeningeal Metastases Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Leptomeningeal Metastases Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Leptomeningeal Metastases Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Leptomeningeal Metastases Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Leptomeningeal Metastases Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Leptomeningeal Metastases Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Leptomeningeal Metastases Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Leptomeningeal Metastases Appendix<\/p>\n<p style=\"text-align: justify;\">18. Leptomeningeal Metastases Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=leptomeningeal-metastases-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-plus-therapeutics-ymabs-therapeutics-angiochem-unicancer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=leptomeningeal-metastases-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-plus-therapeutics-ymabs-therapeutics-angiochem-unicancer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Leptomeningeal Metastases Market size was valued at USD 1,275.4 Million in the year 2021 and the report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/leptomeningeal-metastases-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-plus-therapeutics-ymabs-therapeutics-angiochem-unicancer_696205.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-696205","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/696205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=696205"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/696205\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=696205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=696205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=696205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}